BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26931075)

  • 1. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
    Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
    Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
    Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
    Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4(+) memory T cells in mice.
    Liang H; Liao C; Qi Z; Sha C; Xie B; Chen J; Xia J; Wang Y; Yao Q; Zhao Y
    Transpl Immunol; 2010 Feb; 22(3-4):128-36. PubMed ID: 19755159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
    Gallon L; Traitanon O; Yu Y; Shi B; Leventhal JR; Miller J; Mas V; L X; Mathew JM
    Transplantation; 2015 Sep; 99(9):1774-84. PubMed ID: 25905982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
    Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
    Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus.
    Demmers MW; Baan CC; Janssen M; Litjens NH; Ijzermans JN; Betjes MG; Weimar W; Rowshani AT
    Transplantation; 2014 Jan; 97(1):47-55. PubMed ID: 24157471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation.
    Matz M; Fabritius K; Liu J; Lorkowski C; Brakemeier S; Unterwalder N; Dürr M; Mashreghi MF; Neumayer HH; Budde K
    Transpl Immunol; 2015 Nov; 33(3):176-84. PubMed ID: 26478531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates.
    Kim JS; Lee JI; Shin JY; Kim SY; Shin JS; Lim JH; Cho HS; Yoon IH; Kim KH; Kim SJ; Park CG
    Transplantation; 2009 Dec; 88(12):1349-59. PubMed ID: 20029331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression.
    Chen CC; Koenig A; Saison C; Dahdal S; Rigault G; Barba T; Taillardet M; Chartoire D; Ovize M; Morelon E; Defrance T; Thaunat O
    Front Immunol; 2018; 9():275. PubMed ID: 29515582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
    Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
    Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
    Han JL; Zimmerer JM; Zeng Q; Chaudhari SR; Hart M; Satoskar AA; Abdel-Rasoul M; Breuer CK; Bumgardner GL
    Transplantation; 2024 Mar; 108(3):679-692. PubMed ID: 37872660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells.
    De Bruyne R; Bogaert D; De Ruyck N; Lambrecht BN; Van Winckel M; Gevaert P; Dullaers M
    Clin Exp Immunol; 2015 Jun; 180(3):542-50. PubMed ID: 25682989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine.
    Morelon E; Lefrançois N; Besson C; Prévautel J; Brunet M; Touraine JL; Badet L; Touraine-Moulin F; Thaunat O; Malcus C
    Transpl Immunol; 2010 May; 23(1-2):53-8. PubMed ID: 20406686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
    Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
    Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.